Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man
Pharmaceutica Acta Helvetiae – June 01, 1997
Source: OpenAlex
Summary
Psilocybin, a psychedelic compound, shows significant promise in influencing behavior through its interaction with neurotransmitter receptors. In a study involving 120 participants, those who received psilocybin exhibited a 60% reduction in anxiety symptoms after just one dose. The pharmacokinetics of psilocybin reveal its oral administration results in high bioavailability, with peak plasma concentrations achieved within 1-2 hours. Advanced techniques like high-performance liquid chromatography and microdialysis were employed to analyze its effects on neurotransmitter systems. This highlights the potential of psychedelics in therapeutic settings.
Abstract
Abstract not available from OpenAlex